Stem Cells in Regenerative Medicine

Stem Cells in Regenerative Medicine

Benchmarking Analysis of Big Companies Entering the Market

Price:	$ 1,495.00 (Hardcopy, Print Edition) $ 2,495.00 (PDF Single-Department License) $ 3,995.00 (PDF Corporate-Wide License)
Published:	December 15, 2011
Total Page:	173 pages

This report reviews and analyzes the big healthcare companies that are entering the field of stem cells in regenerative medicine and stem cells in drug discovery. The research report uses the case study format to benchmark the biggest pharmaceutical or life science tools companies that have entered the stem cell market.

The Big Pharma companies are working with the stem cells in regenerative medicine to develop new cell therapies to will help grow their future pipelines. The report reviews what new stem cell based therapies might become available. The drug makers have also become interested in the potential opportunity to improve their chances for making safer future drugs by using pluripotent stem cells, such as human embryonic stem cells (hESCs) or induced pluripotent stemcells (iPSCs), as well as various kinds of adult stem cells to make customized, disease focused cells used in cell screening campaigns in drug discovery toxicity or efficacy testing. The customized human stem cell-derived cells would eliminate the need to sacrifice millions of lab animals that are currently used in drug safety testing.

The study uncovers interesting information about major life science research tools companies working in the stem cell field that supply key products and services to pharma and academic life science researchers working in stem cell R&D. The report reviews the sources of government and private stem cell research investment. Research and development work in all forms of stem cells is underway at universities, government labs, institutes, cancer centers, hospitals and at drug makers or cell therapeutics companies.

This research report is designed for people that include marketers, business development, top executives, investors, VCs, consultants, R&D managers, entrepreneurs and etc. More than 16 detailed tables or figures provide key data about items such as clinical trials, M&As, disease demographics and the like. This report includes seven benchmarking case studies and thirty-eight company profiles that provide the reader with a snapshot of the companies' focus or activities. The provided Internet links help readers access companies' own websites for further review.

Benchmarking Analysis Case of Big Companies Entering the Market
  Common Research Items:
    -Stem Cell Program/Group Overview
    -Strategic Focus for Stem Cell Innovations
    -Major Corp. Deals, Investment, M&A, etc.
    -Stem Cell Related Product Pipeline
    -Stem Cell Related R&D
        R&D Organization
        Research Network including R&D Centers
        Budget
        Number of Researchers
        Target R&D Domain and Noteworthy Area
        Developing Technologies
        R&D to Commercialization Roadmap
    -Analyst's Comment

Table of Contents

1. Overview: Commercializing Stem Cell Business Opportunities in Regenerative Medicine
  1.1 Stem Cells in the Regenerative Medicine Market Space
  1.2 Definitions
    1.2.1 Regenerative Medicine
    1.2.2 Stem cells
    1.2.3 Kinds of Companies
    1.2.4 Origins of Stem Cell Research
  1.3 Estimated Business Opportunity
    1.3.1 The Stem Cells in Drug Discovery Testing
    1.3.2 Stem Cells in Regenerative Medicine Therapy

2. Worldwide Stem Cell Legal Update
  2.1 Overview
  2.2 North America
    2.2.1 Canada
    2.2.2 USA
      2.2.2.1 2001-2009 President Bush's Stem Cell Rules Were in Effect
      2.2.2.2 Apr.-2009, President Obama Reversed The President Bush Restrictions
                           On Embryonic Stem Cell Research
      2.2.2.3 Sept.-2010, Sherley v. Sibellius Lawsuit Court Decision and The Dickey-Wicker
                           Amendment
      2.2.2.4 Apr.-2011, Obama Administration Won Its Appeal To The 'Sherley v.
                           Sibellius Decision'
      2.2.2.5 NIH Approved More hESC Lines
      2.2.2.6 The FDA Approved A Cell Therapy Product
      2.2.2.7 FDA Approved New hES Cell Therapy Clinical Trials
    2.2.3 US States
      2.2.3.1 California
  2.3 Europe
    2.3.1 United Kingdom
    2.3.2 France
    2.3.3 Germany
    2.3.4 Belgium
    2.3.5 Italy
    2.3.6 Sweden
    2.3.7 Spain
  2.4 Middle East
    2.4.1 Israel
    2.4.2 Saudi Arabia
    2.4.3 Iran
  2.5 Asia
    2.5.1 Japan
    2.5.2 South Korea
    2.5.3 India
    2.5.4 China
  2.6 Oceania
    2.6.1 Australia
    2.6.2 New Zealand
  2.7 Latin America
    2.7.1 Brazil
    2.7.2 Mexico
  2.8 Africa
    2.8.1 South Africa

3. Competitive Benchmarking Analysis Cases of Big Companies Working in Stem Cells
  3.1 Pfizer, Inc.
    3.1.1 Stem Cell Program/Group Overview
    3.1.2 Strategic Focus for Stem Cell Innovations
    3.1.3 Major Corp. Deals, Investment, M&A, etc.
    3.1.4 Stem Cell Related Product Pipeline
    3.1.5 Stem Cell Related R&D
      3.1.5.1 R&D Organization
      3.1.5.2 Research Network including R&D Centers
      3.1.5.3 Budget
      3.1.5.4 Number of Researchers
      3.1.5.5 Target R&D Domain and Noteworthy Area
      3.1.5.6 Developing Technologies
      3.1.5.7 R&D to Commercialization Roadmap
    3.1.6 Analyst's Comment
  3.2 Novartis AG
    3.2.1 Stem Cell Program/Group Overview
    3.2.2 Strategic Focus for Stem Cell Innovations
    3.2.3 Major Corp. Deals, Investment, M&A, etc.
    3.2.4 Stem Cell Related Product Pipeline
    3.2.5 Stem Cell Related R&D
      3.2.5.1 R&D Organization
      3.2.5.2 Research Network including R&D Centers
      3.2.5.3 Budget
      3.2.5.4 Number of Researchers
      3.2.5.5 Target R&D Domain and Noteworthy Area
      3.2.5.6 Developing Technologies
      3.2.5.7 R&D to Commercialization Roadmap
    3.2.6 Analyst's Comment
  3.3 Sanofi SA
    3.3.1 Stem Cell Program/Group Overview
    3.3.2 Strategic Focus for Stem Cell Innovations
    3.3.3 Major Corp. Deals, Investment, M&A, etc.
    3.3.4 Stem Cell Related Product Pipeline
    3.3.5 Stem Cell Related R&D
      3.3.5.1 R&D Organization
      3.3.5.2 Research Network including R&D Centers
      3.3.5.3 Budget
      3.3.5.4 Number of Researchers
      3.3.5.5 Target R&D Domain and Noteworthy Area
      3.3.5.6 Developing Technologies
      3.3.5.7 R&D to Commercialization Roadmap
    3.3.6 Analyst's Comment
  3.4 GlaxoSmithKline
    3.4.1 Stem Cell Program/Group Overview
    3.4.2 Strategic Focus for Stem Cell Innovations
    3.4.3 Major Corp. Deals, Investment, M&A, etc.
    3.4.4 Stem Cell Related Product Pipeline
    3.4.5 Stem Cell Related R&D
      3.4.5.1 R&D Organization
      3.4.5.2 Research Network including R&D Centers
      3.4.5.3 Budget
      3.4.5.4 Number of Researchers
      3.4.5.5 Target R&D Domain and Noteworthy Area
      3.4.5.6 Developing Technologies
      3.4.5.7 R&D to Commercialization Roadmap
    3.4.6 Analyst's Comment
  3.5 AstraZeneca
    3.5.1 Stem Cell Program/Group Overview
    3.5.2 Strategic Focus for Stem Cell Innovations
    3.5.3 Major Corp. Deals, Investment, M&A, etc.
    3.5.4 Stem Cell Related Product Pipeline
    3.5.5 Stem Cell Related R&D
      3.5.5.1 R&D Organization
      3.5.5.2 Research Network including R&D Centers
      3.5.5.3 Budget
      3.5.5.4 Number of Researchers
      3.5.5.5 Target R&D Domain and Noteworthy Area
      3.5.5.6 Developing Technologies
      3.5.5.7 R&D to Commercialization Roadmap
    3.5.6 Analyst's Comment
  3.6 Roche
    3.6.1 Stem Cell Program/Group Overview
    3.6.2 Strategic Focus for Stem Cell Innovations
    3.6.3 Major Corp. Deals, Investment, M&A, etc.
    3.6.4 Stem Cell Related Product Pipeline
    3.6.5 Stem Cell Related R&D
      3.6.5.1R&D Organization
      3.6.5.2 Research Network including R&D Centers
      3.6.5.3 Budget
      3.6.5.4 Number of Researchers
      3.6.5.5 Target R&D Domain and Noteworthy Area
      3.6.5.6 Developing Technologies
      3.6.5.7 R&D to Commercialization Roadmap
    3.6.6 Analyst's Comment (Jay to write)
  3.7 GE Healthcare Life Sciences
    3.7.1 Stem Cell Program/Group Overview
    3.7.2 Strategic Focus for Stem Cell Innovations
    3.7.3 Major Corp. Deals, Investment, M&A, etc.
    3.7.4 Stem Cell Related Product Pipeline
    3.7.5 Stem Cell Related R&D
      3.7.5.1 R&D Organization
      3.7.5.2 Research Network including R&D Centers
      3.7.5.3 Budget
      3.7.5.4 Number of Researchers
      3.7.5.5 Target R&D Domain and Noteworthy Area
      3.7.5.6 Developing Technologies
      3.7.5.7 R&D to Commercialization Roadmap
    3.7.6 Analyst's Comment

4. Activities of Companies in Stem Cell R&D
  4.1 Big Pharma Companies
    4.1.1 Astellas Pharma, Inc.
    4.1.2 Johnson and Johnson
    4.1.3 Shire plc
    4.1.4 Takeda Pharmaceutical Co. Ltd.
    4.1.5 Teva Pharmaceuticals Ltd.
  4.2 Cell Therapy Developers
    4.2.1 Advanced Cell Technology
    4.2.2 Athersys, Inc.
    4.2.3 BioTime, Inc.
    4.2.4 Capricor Inc.
    4.2.5 Dendreon Corporation
    4.2.6 Fate Therapeutics, Inc.
    4.2.7 Geron Corporation
    4.2.8 Mesoblast Ltd
    4.2.9 Pluristem Therapeutics
  4.3 Research Tools & Technology Companies
    4.3.1 America Stem Cell Inc.
    4.3.2 Beckman Coulter, Inc. (Danaher)
    4.3.3 Becton, Dickinson & Co.
    4.3.4 Merck KGaA/ EMD Millipore Corporation
    4.3.5 GIRUS Life Sciences, Inc.
    4.3.6 Life Techologies, Inc.
    4.3.7 Luminex Corporation
    4.3.8 PerkinElmer, Inc.
    4.3.9 SABioscience Corporation (Qiagen)
    4.3.10 Sigma-Aldrich Corporation
    4.3.11 TAP Biosystems
    4.3.12 Tecan Group Ltd.
    4.3.13 Thermo Fisher Scientific Inc.
  4.4 Stem Cell Line Manufacturers
    4.4.1 AuxoCell Laboratories, Inc.
    4.4.2 Axiogenesis AG
    4.4.3 Axxam SpA
    4.4.4 California Stem Cell, Inc.
    4.4.5 Cellular Dynamics International
    4.4.6 iPierian, Inc.
    4.4.7 Lonza AG
  4.5 Medical Device Companies
    4.5.1 Baxter International Inc.
    4.5.2 MaxCyte, Inc.
    4.5.3 Cytori Therapeutics, Inc.
    4.5.4 Medtronic, Inc.

5. Commercial Opportunities Identified for Stem Cells in Regenerative Medicine
  5.1 Key Findings
    5.1.1 Big Companies Entered the Stem Cell Field with Need for Partners.
    5.1.2 US Federal Funding Continues for Embryonic Stem Cell Research
    5.1.3 European High Court Banned hESC Methods Patents
    5.1.4 Venture Capital Averse to Biotech and Stem Cell Companies
    5.1.5 Congress' Automatic Deficit Plan to Stem Cell Research Funding
  5.2 Analyst's Benchmarking Summary
  5.3 Likely Opportunities and Challenges
    5.3.1 Political Stem Cell Controversies Expanded Public Interest and Awareness of the
            Medical Benefits of Stem Cell Research
    5.3.2 Challenges to Stem Cell Research
    5.3.3 Global Investment Spending for Stem Cell Research to 2016
  5.4 Commercial Implications
    5.4.1 Opportunities for American and European Companies
      5.4.1.1 Stem Cell Research Tools
      5.4.1.2 Explore Other WW Regions for Cost Savings or New Customers
      5.4.1.3 Asia Offers Business Opportunities
    5.4.2 New Opportunities for Japanese and Asian Companies

6. Appendix
  6.1 Glossary of Terms: Stem Cells in Regenerative Medicine
  6.2 Industry and Company Contacts
  6.3 Big Company Benchmarking Summary Data

List of Tables
      Table 1. Highlights of Stem Cell Research Milestones
      Table 2. Pfizer's Regenerative Medicine Pipeline
      Table 3. Novartis' Stem Cell Related Product Pipeline
      Table 4. Sanofi's Regenerative Medicine Pipeline
      Table 5. GSK's Regenerative Medicine Related Pipeline
      Table 6. AstraZeneca's Regenerative Medicine Pipeline
      Table 7. Roche's Stem Cell Related Product Pipeline
      Table 8. GEHC Stem Cell Related Product Pipeline
      Table 9. Global Investment Spending for Stem Cell Research to 2016
      Table 10. Glossary of Stem Cell Terms
      Table 11. Large International Life Science R&D Centers
      Table 12. Selected Company Contacts
      Table 13. Big Companies by Summary of Stem Cell R&D Data Estimates

List of Illustrations
      Figure 1. Stem Cells in the Regenerative Medicine Market Space
      Figure 2. PubMed Articles about Stem Cells Are Growing
      Figure 3. The Drug Discovery Process
      Figure 4. Retina From a Patient Affected with AMD



FOR ORDER OR INQUIRY, PLEASE CLICK "ORDER / INQUIRY FORM"